An interventional study of Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale. in Hereditary Cancer Syndromes and Clinical Decision Support, sponsored by Nest Genomics. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Nest Genomics · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 with no phase, reaches primary completion later than 3 of the 18 other live ones, and was the 24th registered.
47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.
Browse Neoplastic Syndromes, Hereditary studies →19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 21–75 · Women only
Columbia University · Sites in United States
Ages 18–55 · Women only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18–55 · Women only
Shwachman-Diamond Syndrome Alliance Inc · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 545 across 23 interventional studies indexed under Neoplastic Syndromes, Hereditary.
Median enrollment 588 across the 18 interventional studies, 1,000 across the 15 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 33 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nest Genomics as lead sponsor.
Nest Genomics has 1 study filed under Neoplastic Syndromes, Hereditary — fewer than ten, so there is no comparison to draw.
5 of the studies in Neoplastic Syndromes, Hereditary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05664867University of Illinois at ChicagoImplementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC) | 2026-12 |
| NCT06096688Weill Medical College of Cornell UniversityDiscovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | 2026-12-31 |
| NCT06654466Nest GenomicsClosing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer | 2027-03 |
| NCT07052266Weill Medical College of Cornell UniversityTrial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | 2027-06 |
| NCT07053813University of WashingtonApplying Population Management Best Practices to Preventative Genomic Medicine Trial | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer.
The trial will also help improve the software platform (Nest). The main questions it aims to answer are:
Researchers will compare Nest users to non-users to see if the Nest users are more likely to do recommended cancer screening.
Participants will:
The overall objective of this project is to refine and study Nest, a software platform that integrates genetic data into patient care, with a goal of improving adherence to recommended care and empowering patients and clinicians to utilize genetic information longitudinally. Nest stores structured genetic results in the electronic medical record (EMR) and provides an interface for clinicians to order guidelines-based, personalized care plans with automated charting. For patients, the mobile friendly platform serves as a secure tool to store results, understand risks and recommended care, adhere to care, and share results with at-risk relatives. To facilitate continuity of care, patients can share genetic results and care plans with other clinicians. For this application, the investigators propose two phases. During Phase 1, the investigators will pilot the EMR-integrated Nest platform to ensure that the intervention is feasible and acceptable to clinicians and patients. Phase 2 will test Nest efficacy to improve patient and clinician experiences and outcomes, including patient knowledge of cancer risks and recommended care, and will assess implementation outcomes to facilitate future dissemination. The investigators will leverage a team with complementary expertise in genomic data, business, software development, and care of young adults with cancer risk. This team has already successfully collaborated in development of a patient-facing intervention for adolescents and young adults (AYAs) with cancer risk syndromes, and now seeks to meet the critical need for integrated and coordinated care, crossing patients, clinicians, and health systems. The long-term goal of this application is to harness an EMR integrated platform to improve care and outcomes for AYAs with cancer risk syndromes, as an initial step toward genomic data integration for an ever-increasing array of conditions with clinical implications.
Phase 1 Aims:
Aim 1: Pilot Nest among 20 young adult hereditary cancer patients and up to 20 clinicians, refining implementation to ensure feasibility and acceptability. Our working hypothesis is that the Nest intervention will be feasible and acceptable to patients and clinicians.
Phase 2 Aims:
In Phase 2, the investigators will Implement the Nest intervention by conducting a randomized trial at a single large cancer center and its associated community-based satellites.
Aim 1: Measure the impact of the Nest intervention on patient knowledge of cancer risk and recommended care, psychological distress, and information sharing with family and clinicians.
Our working hypothesis is that patients assigned to the Nest intervention will have increased knowledge of cancer risks and recommended care, without increased psychological distress, and will have increased frequency of information sharing with family and other clinicians.
Aim 2: Examine impact of the Nest intervention on clinician behavior, including guideline-concordant orders and referrals as well as EMR documentation. Our working hypothesis is that patients assigned to the Nest intervention will have higher rates of guidelines-concordant orders and referrals and Nest Clinical Decision Support (CDS) summaries in EMR documentation.
Aim 3: Evaluate implementation outcomes, including patient and clinician utilization of Nest features, to facilitate future dissemination. The investigators will examine the frequency of utilization of Nest features, including patient access and sharing of information and clinician use of orders and documentation templates, to assess features that are most useful and/or in need of further refinement.
Impact: At the completion of the proposed research, our expected outcomes are: to have a refined platform that results in increased knowledge, information sharing, and guidelines concordant care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in the control arm will complete a standard genetic counseling or follow-up visit and a post-visit survey.
Patients in the intervention arm will complete a genetic counseling or follow-up visit with a clinician using Nest Clinical Decision Support and a post visit-survey. Intervention arm patients will be given access to the Nest Patient Navigator.
Device: Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.
The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
Acceptability of Intervention Measure (AIM)
A 4-item measure of intervention acceptability on a 5-point Likert response scale designed for a range of stakeholders. Demonstrated to be associated with intervention success.
Time frame: within 7 days of visit
Gist Comprehension of Genetic Cancer Risk
Modified items from the Gist Comprehension of Genetic Cancer Risk (alpha=.85) ask patients their likelihood of future cancer on a 5-point Likert scale, higher score indicating greater comprehension.
Time frame: Baseline, within 7 days of visit
Knowledge of Cancer Screening
An 11-item true-false scale (Cronbach's alpha=.81) will measure knowledge of cancer screening recommendations. Higher score indicates greater knowledge, minimum score=0, maximum score=11. Items will be modified for cancer risk syndromes under study.
Time frame: Baseline, within 7 days of visit
Psychosocial Aspects of Hereditary Cancer (PAHC)
A 26-item questionnaire organized into six problem domains: genetics, practical issues, family, living with cancer, emotions, and children. Higher score indicates greater emotional distress. Validated in adults with hereditary cancer risk.
Time frame: Baseline, within 7 days of visit
Distress Thermometer (DT)
A visual-analog scale from 0-"no distress" to 10-"extreme distress" to assess general psychological distress. Higher score indicates greater distress. Pairing with the PAHC enhances sensitivity and specificity.
Time frame: Baseline, within 7 days of visit
Uncertainty of Illness Measures
self-report - Mischel Illness Uncertainty Scale (Cronbach's α=.74-.92).5-point Likert scale ranging from "Strongly Agree" to "Strongly Disagree". Higher scores indicate greater uncertainty.
Time frame: Baseline, within 7 days of visit
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Syndromes, Hereditary →